Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) (2018 - 2025)
Historic EPS (Weighted Average and Diluted) for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q3 2025 value amounting to -$0.16.
- Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) fell 12909.09% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.67, marking a year-over-year increase of 6084.34%. This contributed to the annual value of $2.17 for FY2024, which is 14942.68% up from last year.
- Per Biomarin Pharmaceutical's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.16 for Q3 2025, which was down 12909.09% from $1.23 recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year EPS (Weighted Average and Diluted) high stood at $1.23 for Q2 2025, and its period low was -$0.32 during Q4 2021.
- Its 5-year average for EPS (Weighted Average and Diluted) is $0.29, with a median of $0.21 in 2023.
- In the last 5 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) crashed by 39090.91% in 2021 and then skyrocketed by 768887.55% in 2023.
- Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.32 in 2021, then skyrocketed by 99.59% to -$0.0 in 2022, then surged by 7688.88% to $0.1 in 2023, then soared by 535.17% to $0.64 in 2024, then crashed by 125.19% to -$0.16 in 2025.
- Its last three reported values are -$0.16 in Q3 2025, $1.23 for Q2 2025, and $0.95 during Q1 2025.